GSNO as a Modulator of Vascular Tone in Human Saphenous Veins: Potential Implications for Graft Spasm
S-nitrosoglutathione (GSNO), a promising S-nitrosothiol, has been recognized for its ability to modulate vascular tone through its vasodilatory, antiplatelet, and antiproliferative effects. However, data on its vasodilatory effects in human vessels remain limited, and its mechanisms of action have y...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/15/7/1139 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | S-nitrosoglutathione (GSNO), a promising S-nitrosothiol, has been recognized for its ability to modulate vascular tone through its vasodilatory, antiplatelet, and antiproliferative effects. However, data on its vasodilatory effects in human vessels remain limited, and its mechanisms of action have yet to be fully elucidated. In this study, we aimed to investigate the vasorelaxant effect of GSNO and its underlying mechanisms, with particular focus on the soluble guanylate cyclase (sGC)/nitric oxide (NO) pathway and potassium channels in isolated human saphenous veins (SVs) obtained from patients undergoing coronary artery bypass grafting (CABG). GSNO (10<sup>−8</sup>–10<sup>−4</sup> M) produced concentration-dependent relaxations in SV rings precontracted with phenylephrine. These relaxations were unaffected by NO synthase inhibition with L-NAME (10<sup>−4</sup> M, 30 min) or NO scavenging with PTIO (10<sup>−4</sup> M, 30 min), but were significantly reduced by the sGC inhibitor, ODQ (10<sup>−5</sup> M, 30 min). Inhibition of ATP-sensitive (glibenclamid; 10<sup>−5</sup> M, 30 min.), high-conductance Ca<sup>2+</sup>-activated (charybdotoxin; 10<sup>−7</sup> M, 30 min), small-conductance Ca<sup>2+</sup>-activated (apamin; 10<sup>−6</sup> M, 30 min), or voltage-dependent (4-aminopyridine; 10<sup>−3</sup> M, 30 min) potassium channels did not alter the maximum relaxant responses to GSNO. Furthermore, pretreatment with GSNO (10<sup>−4</sup> M, 30 min) significantly attenuated both the contractile response and sensitivity to phenylephrine. Collectively, these findings demonstrate that GSNO exerts acute vasorelaxant and modulatory effects in human SV primarily via cGMP-dependent mechanisms, highlighting its potential as a local therapeutic agent for preventing graft spasm in CABG. |
|---|---|
| ISSN: | 2075-1729 |